Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Medications Don’t Slow T2D Progression in Youth

Diabetes Care; ePub 2018 Jun 25; RISE Consortium

In youth with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes (T2D), neither 3 months of glargine followed by 9 months of metformin nor 12 months of metformin alone slowed the progressive deterioration of β-cell function, a recent study found. 91 pubertal, overweight/obese youth aged 10-19 years with IGT (60%) or T2D of <6 months duration (40%) were randomized to either 3 months of insulin glargine with a target glucose of 4.4-5.0 mmol/L followed by 9 months of metformin or to 12 months of metformin alone. Researchers found:

  • No significant differences were found between treatment groups as baseline, 12 months, or 15 months in β-cell function, body mass index (BMI) percentile, HbA1c fasting glucose, or oral glucose tolerance test 2-h glucose results.
  • In both treatment groups, clamp-measured β-cell function was significantly lower at 12 and 15 months vs baseline.
  • HbA1c fell transiently at 6 months within both groups.
  • BMI was higher in the glargine followed by metformin vs metformin alone group between 3-9 months.


The RISE Consortium. Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. [Published online ahead of print June 25, 2018]. Diabetes Care. doi:10.2337/dc18-0787.